Nepexto, Enbrel Biosimilar, Approved to Treat Patients in Europe

Nepexto, Enbrel Biosimilar, Approved to Treat Patients in Europe
5
(1)

Nepexto, a biosimilar to Enbrel (etanercept), has been approved by the European Commission to treat ankylosing spondylitis (AS) and several other inflammatory disorders.

The therapy, co-developed by Mylan and Lupin, is expected to be available to patients in the European Union in the second half of the year, Mylan stated in a press release.

The announcement follows a recommendation made by the Committee for Medicinal Products for Human Use (CHMP), a branch of the European Medicines Agency.

Besides AS, Nepexto can be used by people all indications for Enbrel in the EU, namely rheumatoid arthritispsoriatic arthritis, adult and pediatric plaque psoriasis, and both forms of axial spondyloarthritis — AS and non-radiographic axial spondyloarthritis.

CHMP had based its assessment on preclinical and clinical studies showing that Nepexto has similar active properties, and comparable safety and efficacy, with Enbrel, which is manufactured by Amgen.

A Phase 3 clinical study (2015-002809-12) also confirmed equivalent efficacy, safety, and immunogenicity — the capacity to induce an immune response — between Nepexto and Enbrel among patients with moderate-to-severe rheumatoid arthritis.

Biosimilars are to biological therapies what generics are to conventional medications. They have comparable safety, efficacy, dosing, and route of administration to a reference biologic, and are manufactured by a different company after the original product’s patent expires. Usually, biosimilars are sold at considerably lower prices than reference treatments.

Nepexto joins two other biosimilars for Enbrel that have been approved in Europe: Erelzi, by Novartis, and Benepali, by Samsung Bioepis. All work by blocking a pro-inflammatory protein called tumor necrosis factor.

“We are truly delighted with this approval. Nepexto is our first biosimilar to receive regulatory approval in Europe. With this important milestone, we bring an affordable biosimilar to the European market through our partner Mylan. Biosimilars like Nepexto will play a critical role in expanding access to patients in Europe,” Vinita Gupta, CEO of Lupin, said in the release.

Added Rajiv Malik, Mylan’s president: “The approval of Nepexto, our biosimilar etanercept, is a positive step forward as we work to broaden our biosimilars franchise offerings and do our part to increase access to biologic treatments for patients in many European countries.”

The companies previously announced plans to request their biosimilar be approved for patients outside of Europe as well.

Forest Ray received his PhD in systems biology from Columbia University, where he developed tools to match drug side effects to other diseases. He has since worked as a journalist and science writer, covering topics from rare diseases to the intersection between environmental science and social justice. He currently lives in Long Beach, California.
Total Posts: 10
José is a science news writer with a PhD in Neuroscience from Universidade of Porto, in Portugal. He has also studied Biochemistry at Universidade do Porto and was a postdoctoral associate at Weill Cornell Medicine, in New York, and at The University of Western Ontario in London, Ontario, Canada. His work has ranged from the association of central cardiovascular and pain control to the neurobiological basis of hypertension, and the molecular pathways driving Alzheimer’s disease.
×
Forest Ray received his PhD in systems biology from Columbia University, where he developed tools to match drug side effects to other diseases. He has since worked as a journalist and science writer, covering topics from rare diseases to the intersection between environmental science and social justice. He currently lives in Long Beach, California.
Latest Posts
  • Hulio approved by FDA
  • rare disease survey

How useful was this post?

Click on a star to rate it!

Average rating 5 / 5. Vote count: 1

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?